lorazepam has been researched along with Status Epilepticus in 153 studies
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.
Status Epilepticus: A prolonged seizure or seizures repeated frequently enough to prevent recovery between episodes occurring over a period of 20-30 minutes. The most common subtype is generalized tonic-clonic status epilepticus, a potentially fatal condition associated with neuronal injury and respiratory and metabolic dysfunction. Nonconvulsive forms include petit mal status and complex partial status, which may manifest as behavioral disturbances. Simple partial status epilepticus consists of persistent motor, sensory, or autonomic seizures that do not impair cognition (see also EPILEPSIA PARTIALIS CONTINUA). Subclinical status epilepticus generally refers to seizures occurring in an unresponsive or comatose individual in the absence of overt signs of seizure activity. (From N Engl J Med 1998 Apr 2;338(14):970-6; Neurologia 1997 Dec;12 Suppl 6:25-30)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This randomized control study was conducted to compare the efficacy of sodium valproate (SVP) and levetiracetam (LEV) following initial intravenous lorazepam in elderly patients (age: >60years) with generalized convulsive status epilepticus (GCSE) and to identify predictors of poor seizure control." | 9.30 | Comparing the efficacy of sodium valproate and levetiracetam following initial lorazepam in elderly patients with generalized convulsive status epilepticus (GCSE): A prospective randomized controlled pilot study. ( Bharath, RD; Bindu, PS; Mundlamuri, RC; Nagappa, M; Nene, D; Prathyusha, PV; Raghavendra, K; Saini, J; Satishchandra, P; Sinha, S; Taly, AB; Thennarasu, K, 2019) |
| "Diazepam is labeled for status epilepticus (SE) in children, but there are limited data characterizing its disposition in pediatric patients." | 9.27 | Population Pharmacokinetics and Exploratory Exposure-Response Relationships of Diazepam in Children Treated for Status Epilepticus. ( Anand, R; Beechinor, RJ; Capparelli, EV; Chamberlain, JM; Cohen-Wolkowiez, M; Gonzalez, D; Guptill, JT; Harper, B; Hornik, CP; Ku, LC; Martz, K, 2018) |
| "This was a secondary analysis of the efficacy and safety results of the Pediatric Seizure Study, a randomized clinical trial of lorazepam versus diazepam for pediatric status epilepticus." | 9.24 | Making Sense of a Negative Clinical Trial Result: A Bayesian Analysis of a Clinical Trial of Lorazepam and Diazepam for Pediatric Status Epilepticus. ( Chamberlain, DB; Chamberlain, JM, 2017) |
| "To examine the effectiveness of intramuscular (IM) midazolam versus intravenous (IV) lorazepam for the treatment of pediatric patients with status epilepticus (SE) in the prehospital care setting." | 9.20 | Intramuscular midazolam versus intravenous lorazepam for the prehospital treatment of status epilepticus in the pediatric population. ( Conwit, R; Durkalski-Mauldin, VL; Lewandowski, C; Lowenstein, DH; Mahajan, PV; Nicholas, K; Silbergleit, R; Welch, RD, 2015) |
| "For the management of status epilepticus (SE), lorazepam (LOR) is recommended as the first and phenytoin or fosphenytoin as the second choice." | 9.16 | Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study. ( Kalita, J; Maurya, PK; Misra, UK, 2012) |
| " RAMPART (Rapid Anticonvulsant Medication Prior to Arrival Trial) is a double-blind randomized clinical trial to determine if the efficacy of IM midazolam is noninferior by a margin of 10% to that of intravenous (IV) lorazepam in patients treated by paramedics for status epilepticus (SE)." | 9.15 | RAMPART (Rapid Anticonvulsant Medication Prior to Arrival Trial): a double-blind randomized clinical trial of the efficacy of intramuscular midazolam versus intravenous lorazepam in the prehospital treatment of status epilepticus by paramedics. ( Conwit, R; Durkalski, V; Lowenstein, D; Silbergleit, R, 2011) |
| "To determine whether intravenous lorazepam is as efficacious as diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children." | 9.14 | Lorazepam versus diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children: a randomized controlled trial. ( Gupta, P; Krishnamurthy, S; Sharma, KK; Sreenath, TG, 2010) |
| "Lorazepam was compared with diazepam for the treatment of acute convulsions and status epilepticus in 102 children in a prospective, open, 'odd and even dates' trial." | 9.08 | Lorazepam versus diazepam in the acute treatment of epileptic seizures and status epilepticus. ( Appleton, R; Choonara, I; Molyneux, E; Robson, J; Sweeney, A, 1995) |
| "Lorazepam was compared with diazepam for the treatment of status epilepticus in a double-blind, randomized trial." | 9.05 | Double-blind study of lorazepam and diazepam in status epilepticus. ( Derivan, AT; Homan, RW; Leppik, IE; Patrick, B; Ramsay, RE; Walker, J, 1983) |
| "Midazolam, lorazepam, and diazepam were recommended as emergent initial therapy for status epilepticus." | 8.93 | A Comparison of Midazolam, Lorazepam, and Diazepam for the Treatment of Status Epilepticus in Children: A Network Meta-analysis. ( Fan, JC; Feng, K; Wang, HY; Wen, B; Yang, ZB; Zhao, ZY, 2016) |
| "Some guidelines or expert consensus indicate that intravenous (IV) lorazepam (LZP) is preferable to IV diazepam (DZP) for initial treatment of convulsive status epilepticus (SE)." | 8.93 | Is intravenous lorazepam really more effective and safe than intravenous diazepam as first-line treatment for convulsive status epilepticus? A systematic review with meta-analysis of randomized controlled trials. ( Bacigaluppi, S; Bragazzi, NL; Brigo, F; Nardone, R; Trinka, E, 2016) |
| "Patients prescribed sublingual lorazepam solution at the Johns Hopkins Epilepsy Center for acute seizure treatment during a 5-year period (2012-2017) were screened." | 8.31 | Sublingual lorazepam as rescue therapy for seizure emergencies in adults. ( Krauss, GL; Lelis, IR, 2023) |
| "The objective of the study was to compare the performance of intravenous (IV) lorazepam (IVL) and intranasal midazolam (INM) for seizure termination and prevention of seizure clusters in adults admitted to the epilepsy monitoring unit (EMU) in whom seizures were captured on continuous video-electroencephalogram." | 7.91 | Comparison of intranasal midazolam versus intravenous lorazepam for seizure termination and prevention of seizure clusters in the adult epilepsy monitoring unit. ( Bautista, C; Cotugno, S; Deng, Y; Dhakar, MB; Farooque, P; Hirsch, LJ; Maciel, CB; McKimmy, D; Owusu, KA; Sukumar, N, 2019) |
| "A protocol was developed to achieve status epilepticus (SE) resolution: step 1, intramuscular (IM) lorazepam; step 2, repeat IM lorazepam; step 3, rectal diazepam." | 7.85 | Intramuscular Lorazepam for Status Epilepticus in Children With Complex Medical and Physical Disabilities. ( Johnson, M; Johnson, PN; Neely, SB; Nguyen, A, 2017) |
| "Clinical question Is intravenous (IV) lorazepam superior to IV diazepam in the treatment of pediatric status epilepticus? Article chosen Chamberlain JM, Okada P, Holsti M, et al." | 7.83 | Lorazepam v. diazepam for pediatric status epilepticus. ( Pinto, RF; Turnbull, J, 2016) |
| " As a step toward eventual coupling of rTMS with antiepileptic pharmacotherapy, we also tested whether high-frequency rTMS in combination with a low (ineffective but less likely to cause a side effect) lorazepam dose is as effective as a full lorazepam dose in suppressing seizures in a rat SE model." | 7.83 | Bursts of high-frequency repetitive transcranial magnetic stimulation (rTMS), together with lorazepam, suppress seizures in a rat kainate status epilepticus model. ( Dhamne, SC; Gersner, R; Pascual-Leone, A; Rotenberg, A; Zangen, A, 2016) |
| "Benzodiazepines (BZD) are recommended as first-line treatment for status epilepticus (SE), with lorazepam (LZP) and midazolam (MDZ) being the most widely used drugs and part of current treatment guidelines." | 7.81 | Practice variability and efficacy of clonazepam, lorazepam, and midazolam in status epilepticus: A multicenter comparison. ( Alvarez, V; Drislane, FW; Dworetzky, BA; Lee, JW; Novy, J; Rossetti, AO; Westover, MB, 2015) |
| "To evaluate the single dose pharmacokinetics of an intravenous dose of lorazepam in pediatric patients treated for status epilepticus (SE) or with a history of SE." | 7.78 | Pharmacokinetics of intravenous lorazepam in pediatric patients with and without status epilepticus. ( Baren, JM; Brown, KM; Capparelli, EV; Chamberlain, JM; Davis, CO; Gordon, S; Lichenstein, R; Lillis, K; Mahajan, P; Stanley, RM; van den Anker, JN; Vance, CW, 2012) |
| " The pharmacokinetic data favor use of IL instead of its principal therapeutic alternative (injectable diazepam) but no currently available evidence concludes that IL is superior to diazepam in the management of pediatric status epilepticus." | 7.76 | [Use of injectable lorazepam in status epilepticus: a comparative study in French-speaking hospitals]. ( Auvin, S; Bourdon, O; Brion, F; Curatolo, N; Prot-Labarthe, S; Sachs, P, 2010) |
| "A 44-year-old man with treated neurosyphilis presented with subclinical status epilepticus (SE) refractory to intravenous high-dose lorazepam, phenytoin, and valproic acid over 4 days." | 7.72 | Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. ( Lerner, AJ; Maddux, BN; Sagar, SM; Suarez, JI; Ubogu, EE; Werz, MA, 2003) |
| "The aim of this report is to describe the clinical and electroencephalographic findings seen in an elderly woman without previous history of seizures who developed a nonconvulsive generalized status epilepticus following acute withdrawal of lorazepam." | 7.71 | De novo absence status of late onset following withdrawal of lorazepam: a case report. ( Fernández-Torre, JL, 2001) |
| "Previous trials have suggested lorazepam may be superior to diazepam as first-line treatment of convulsive status epilepticus (CSE), with improved seizure outcome, and a lower incidence of side-effects." | 7.71 | A comparison of lorazepam and diazepam as initial therapy in convulsive status epilepticus. ( Cock, HR; Schapira, AH, 2002) |
| "We treated nine refractory status epilepticus cases with high-dose intravenous lorazepam." | 7.69 | High-dose intravenous lorazepam for the treatment of refractory status epilepticus. ( Ali, A; Labar, DR; Root, J, 1994) |
| "We studied the efficacy, pharmacokinetics, and brain entry of lorazepam in the treatment of status epilepticus (SE) using a rat model of secondarily generalized convulsive SE." | 7.68 | Lorazepam treatment of experimental status epilepticus in the rat: relevance to clinical practice. ( Treiman, DM; Walton, NY, 1990) |
| "Twenty-one episodes of status epilepticus (SE) were each treated with 1 to 9 mg (mean, 4 mg) of intravenous lorazepam." | 7.67 | Treatment of status epilepticus with lorazepam. ( Krall, RL; Levy, RJ, 1984) |
| "This report details the management of status epilepticus with high-dose lorazepam in a 14-year-old patient who was receiving oral clonazepam, ethosuximide, and phenobarbital for an intractable seizure disorder." | 7.67 | High-dose lorazepam therapy for status epilepticus in a pediatric patient. ( Gilmore, RL; Kuhn, RJ; Reincke, HM, 1988) |
| "We report our experience with 300 consecutive parenteral doses of lorazepam (LOR) for status epilepticus (SE) or serial seizures in 77 children and young adults." | 7.67 | Lorazepam in childhood status epilepticus and serial seizures: effectiveness and tachyphylaxis. ( Crawford, TO; Mitchell, WG; Snodgrass, SR, 1987) |
| "Primary outcome was seizure cessation for 1h, and secondary outcomes were 24h seizure remission, in-hospital death, and severe adverse events (SAE)." | 6.84 | Comparison of lacosamide versus sodium valproate in status epilepticus: A pilot study. ( Dubey, D; Kalita, J; Misra, UK, 2017) |
| "Lorazepam is likely to be a better therapy than diazepam." | 6.70 | A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. ( Alldredge, BK; Allen, F; Corry, MD; Gelb, AM; Gottwald, MD; Isaacs, SM; Lowenstein, DH; Neuhaus, JM; O'Neil, N; Segal, MR; Ulrich, S, 2001) |
| " It has been shown that lorazepam is commonly under dosed in SE, but there is conflicting data on whether this has a negative impact on patient outcomes." | 5.91 | Evaluation of intravenous lorazepam dosing strategies and the incidence of refractory status epilepticus. ( Cetnarowski, A; Cunningham, B; Fowler, M; Mullen, C, 2023) |
| "Status Epilepticus is the most common non-traumatic neurologic emergency in childhood." | 5.72 | Resolution of status epilepticus after ketamine administration. ( Hakmeh, W; Howing, CE; Razi, F, 2022) |
| " Risk factors for the disease include older age, renal dysfunction, critical illness, and inappropriate dosing based upon renal function." | 5.56 | Cefepime-Induced Neurotoxicity Presenting with Nonconvulsive Status Epilepticus Admitted as a Stroke Alert. ( Allyn, R; Cunningham, JM; Sachs, KV, 2020) |
| " The most common adverse events (AEs) were somnolence (7." | 5.51 | [Efficacy and Safety of Lorazepam Intravenously Administered in Subjects with Status Epilepticus or Repetitive Seizures]. ( Nakasato, N; Nakazuru, Y; Ohtsuka, Y; Terada, M, 2019) |
| "Status epilepticus was induced by intra-amygdala microinjection of kainic acid in 8week old C57Bl/6 mice." | 5.42 | Comparison of short-term effects of midazolam and lorazepam in the intra-amygdala kainic acid model of status epilepticus in mice. ( Diviney, M; Henshall, DC; Reynolds, JP, 2015) |
| " Measurement of serum concentrations and changes in dosing guidelines can probably prevent NCSE during cefepime therapy." | 5.33 | Nonconvulsive status epilepticus due to cefepime in a patient with normal renal function. ( Biswas, A; Jolin, D; Maganti, R; Rishi, D, 2006) |
| "Diazepam rectal gel was given more quickly and reliably, reducing total seizure time, potential neuronal injury and other complications." | 5.32 | Treatment of out-of-hospital status epilepticus with diazepam rectal gel. ( Fitzgerald, BJ; Miller, JW; Okos, AJ, 2003) |
| "This randomized control study was conducted to compare the efficacy of sodium valproate (SVP) and levetiracetam (LEV) following initial intravenous lorazepam in elderly patients (age: >60years) with generalized convulsive status epilepticus (GCSE) and to identify predictors of poor seizure control." | 5.30 | Comparing the efficacy of sodium valproate and levetiracetam following initial lorazepam in elderly patients with generalized convulsive status epilepticus (GCSE): A prospective randomized controlled pilot study. ( Bharath, RD; Bindu, PS; Mundlamuri, RC; Nagappa, M; Nene, D; Prathyusha, PV; Raghavendra, K; Saini, J; Satishchandra, P; Sinha, S; Taly, AB; Thennarasu, K, 2019) |
| "Diazepam is labeled for status epilepticus (SE) in children, but there are limited data characterizing its disposition in pediatric patients." | 5.27 | Population Pharmacokinetics and Exploratory Exposure-Response Relationships of Diazepam in Children Treated for Status Epilepticus. ( Anand, R; Beechinor, RJ; Capparelli, EV; Chamberlain, JM; Cohen-Wolkowiez, M; Gonzalez, D; Guptill, JT; Harper, B; Hornik, CP; Ku, LC; Martz, K, 2018) |
| "Lorazepam appears to be an effective and safe drug for treatment of status epilepticus, with a duration of control longer than that achieved with diazepam." | 5.26 | Lorazepam in status epilepticus. ( Bell, RD; Crawford, IL; Homan, RW; Tasker, WG; Vasko, MR; Walker, JE, 1979) |
| "This was a secondary analysis of the efficacy and safety results of the Pediatric Seizure Study, a randomized clinical trial of lorazepam versus diazepam for pediatric status epilepticus." | 5.24 | Making Sense of a Negative Clinical Trial Result: A Bayesian Analysis of a Clinical Trial of Lorazepam and Diazepam for Pediatric Status Epilepticus. ( Chamberlain, DB; Chamberlain, JM, 2017) |
| " Head-to-head trials comparing buccal versus intranasal midazolam versus rectal diazepam would provide useful information to inform the management of the first stage of convulsive status epilepticus in adults, especially when intravenous or intramuscular access is not feasible." | 5.22 | Management of the first stage of convulsive status epilepticus in adults: a systematic review of current randomised evidence. ( Aucott, L; Booth, C; Brazzelli, M; Counsell, C; Cruickshank, M; Imamura, M; Manson, P; Scotland, G, 2022) |
| "We report the efficacy and safety of lorazepam (LOR), phenytoin (PHT), valproate (VPA) and levetiracetam (LEV) as first and second choice antiepileptic drug (AED) in status epilepticus (SE) and their combinations in preventing refractory SE." | 5.22 | A comparison of four antiepileptic drugs in status epilepticus: experience from India. ( Kalita, J; Misra, UK, 2016) |
| "To examine the effectiveness of intramuscular (IM) midazolam versus intravenous (IV) lorazepam for the treatment of pediatric patients with status epilepticus (SE) in the prehospital care setting." | 5.20 | Intramuscular midazolam versus intravenous lorazepam for the prehospital treatment of status epilepticus in the pediatric population. ( Conwit, R; Durkalski-Mauldin, VL; Lewandowski, C; Lowenstein, DH; Mahajan, PV; Nicholas, K; Silbergleit, R; Welch, RD, 2015) |
| "This was a secondary analysis of data collected as part of the Rapid Anticonvulsant Medication Prior to Arrival Trial (RAMPART), a study comparing intramuscular midazolam to intravenous lorazepam given by paramedics to patients with prehospital status epilepticus." | 5.20 | Accounting for repeat enrollments during an emergency clinical trial: the Rapid Anticonvulsant Medications Prior to Arrival Trial (RAMPART). ( Burke, JF; Durkalski, V; Meurer, WJ; Nicholas, KS; Silbergleit, R, 2015) |
| "For the management of status epilepticus (SE), lorazepam (LOR) is recommended as the first and phenytoin or fosphenytoin as the second choice." | 5.16 | Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study. ( Kalita, J; Maurya, PK; Misra, UK, 2012) |
| "This double-blind, randomized, noninferiority trial compared the efficacy of intramuscular midazolam with that of intravenous lorazepam for children and adults in status epilepticus treated by paramedics." | 5.16 | Intramuscular versus intravenous therapy for prehospital status epilepticus. ( Barsan, W; Conwit, R; Durkalski, V; Lowenstein, D; Palesch, Y; Pancioli, A; Silbergleit, R, 2012) |
| " RAMPART (Rapid Anticonvulsant Medication Prior to Arrival Trial) is a double-blind randomized clinical trial to determine if the efficacy of IM midazolam is noninferior by a margin of 10% to that of intravenous (IV) lorazepam in patients treated by paramedics for status epilepticus (SE)." | 5.15 | RAMPART (Rapid Anticonvulsant Medication Prior to Arrival Trial): a double-blind randomized clinical trial of the efficacy of intramuscular midazolam versus intravenous lorazepam in the prehospital treatment of status epilepticus by paramedics. ( Conwit, R; Durkalski, V; Lowenstein, D; Silbergleit, R, 2011) |
| "To determine whether intravenous lorazepam is as efficacious as diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children." | 5.14 | Lorazepam versus diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children: a randomized controlled trial. ( Gupta, P; Krishnamurthy, S; Sharma, KK; Sreenath, TG, 2010) |
| "Lorazepam was compared with diazepam for the treatment of acute convulsions and status epilepticus in 102 children in a prospective, open, 'odd and even dates' trial." | 5.08 | Lorazepam versus diazepam in the acute treatment of epileptic seizures and status epilepticus. ( Appleton, R; Choonara, I; Molyneux, E; Robson, J; Sweeney, A, 1995) |
| "As initial intravenous treatment for overt generalized convulsive status epilepticus, lorazepam is more effective than phenytoin." | 5.08 | A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. ( Calabrese, VP; Colling, C; Collins, JF; Faught, E; Handforth, A; Mamdani, MB; Meyers, PD; Ramsay, RE; Rowan, AJ; Treiman, DM; Uthman, BM; Walton, NY, 1998) |
| "Lorazepam was compared with diazepam for the treatment of status epilepticus in a double-blind, randomized trial." | 5.05 | Double-blind study of lorazepam and diazepam in status epilepticus. ( Derivan, AT; Homan, RW; Leppik, IE; Patrick, B; Ramsay, RE; Walker, J, 1983) |
| "Midazolam, lorazepam, and diazepam were recommended as emergent initial therapy for status epilepticus." | 4.93 | A Comparison of Midazolam, Lorazepam, and Diazepam for the Treatment of Status Epilepticus in Children: A Network Meta-analysis. ( Fan, JC; Feng, K; Wang, HY; Wen, B; Yang, ZB; Zhao, ZY, 2016) |
| "Some guidelines or expert consensus indicate that intravenous (IV) lorazepam (LZP) is preferable to IV diazepam (DZP) for initial treatment of convulsive status epilepticus (SE)." | 4.93 | Is intravenous lorazepam really more effective and safe than intravenous diazepam as first-line treatment for convulsive status epilepticus? A systematic review with meta-analysis of randomized controlled trials. ( Bacigaluppi, S; Bragazzi, NL; Brigo, F; Nardone, R; Trinka, E, 2016) |
| "Lorazepam is better than diazepam or phenytoin alone for cessation of seizures and carries a lower risk of continuation of status epilepticus requiring a different drug or general anaesthesia." | 4.84 | Anticonvulsant therapy for status epilepticus. ( Al-Roomi, K; Krishnan, PR; Prasad, K; Sequeira, R, 2007) |
| "Lorazepam is better than diazepam or phenytoin alone for cessation of seizures and carries a lower risk of continuation of status epilepticus requiring a different drug or general anaesthesia." | 4.82 | Anticonvulsant therapy for status epilepticus. ( Al-Roomi, K; Krishnan, PR; Prasad, K; Sequeira, R, 2005) |
| "To review the evidence comparing diazepam, lorazepam, phenobarbitone, phenytoin and paraldehyde in treating acute tonic-clonic convulsions and convulsive status epilepticus in children." | 4.81 | Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. ( Appleton, R; Martland, T; Phillips, B, 2002) |
| "This project aimed to retrospectively obtain, review, and extract key safety data from medical records of participants enrolled in RAMPART, the NIH-supported Rapid Anticonvulsant Medication Prior to ARrival Trial of intramuscular midazolam versus intravenous lorazepam for pre-hospital treatment of status epilepticus, to support a US new drug application (NDA) for intramuscular midazolam." | 4.31 | The Midazolam RAMPART Study Medical Records Project: A Unique Use of Real-World Data in a Complex Collaborative Partnership to Support a New Drug Application. ( Bengelink, EM; Durkalski, V; Sherman, NA; Silbergleit, R; Wolter, KD, 2023) |
| "Patients prescribed sublingual lorazepam solution at the Johns Hopkins Epilepsy Center for acute seizure treatment during a 5-year period (2012-2017) were screened." | 4.31 | Sublingual lorazepam as rescue therapy for seizure emergencies in adults. ( Krauss, GL; Lelis, IR, 2023) |
| " Our study aims to assess if administering lorazepam, for convulsive seizures <5 min, causes vital instability." | 3.96 | Lorazepam timing for acute convulsive seizure control (LoTASC). ( Gopal, M; Greene-Chandos, D; Hamed, M; Hussein, O; Kamdar, HA; Peters, E; Sawalha, K; Shanmugam, K; Smetana, KS; Thakur, G; Yasin, R, 2020) |
| "The objective of the study was to compare the performance of intravenous (IV) lorazepam (IVL) and intranasal midazolam (INM) for seizure termination and prevention of seizure clusters in adults admitted to the epilepsy monitoring unit (EMU) in whom seizures were captured on continuous video-electroencephalogram." | 3.91 | Comparison of intranasal midazolam versus intravenous lorazepam for seizure termination and prevention of seizure clusters in the adult epilepsy monitoring unit. ( Bautista, C; Cotugno, S; Deng, Y; Dhakar, MB; Farooque, P; Hirsch, LJ; Maciel, CB; McKimmy, D; Owusu, KA; Sukumar, N, 2019) |
| "A protocol was developed to achieve status epilepticus (SE) resolution: step 1, intramuscular (IM) lorazepam; step 2, repeat IM lorazepam; step 3, rectal diazepam." | 3.85 | Intramuscular Lorazepam for Status Epilepticus in Children With Complex Medical and Physical Disabilities. ( Johnson, M; Johnson, PN; Neely, SB; Nguyen, A, 2017) |
| "Clinical question Is intravenous (IV) lorazepam superior to IV diazepam in the treatment of pediatric status epilepticus? Article chosen Chamberlain JM, Okada P, Holsti M, et al." | 3.83 | Lorazepam v. diazepam for pediatric status epilepticus. ( Pinto, RF; Turnbull, J, 2016) |
| " As a step toward eventual coupling of rTMS with antiepileptic pharmacotherapy, we also tested whether high-frequency rTMS in combination with a low (ineffective but less likely to cause a side effect) lorazepam dose is as effective as a full lorazepam dose in suppressing seizures in a rat SE model." | 3.83 | Bursts of high-frequency repetitive transcranial magnetic stimulation (rTMS), together with lorazepam, suppress seizures in a rat kainate status epilepticus model. ( Dhamne, SC; Gersner, R; Pascual-Leone, A; Rotenberg, A; Zangen, A, 2016) |
| "Benzodiazepines (BZD) are recommended as first-line treatment for status epilepticus (SE), with lorazepam (LZP) and midazolam (MDZ) being the most widely used drugs and part of current treatment guidelines." | 3.81 | Practice variability and efficacy of clonazepam, lorazepam, and midazolam in status epilepticus: A multicenter comparison. ( Alvarez, V; Drislane, FW; Dworetzky, BA; Lee, JW; Novy, J; Rossetti, AO; Westover, MB, 2015) |
| "To evaluate the single dose pharmacokinetics of an intravenous dose of lorazepam in pediatric patients treated for status epilepticus (SE) or with a history of SE." | 3.78 | Pharmacokinetics of intravenous lorazepam in pediatric patients with and without status epilepticus. ( Baren, JM; Brown, KM; Capparelli, EV; Chamberlain, JM; Davis, CO; Gordon, S; Lichenstein, R; Lillis, K; Mahajan, P; Stanley, RM; van den Anker, JN; Vance, CW, 2012) |
| " The pharmacokinetic data favor use of IL instead of its principal therapeutic alternative (injectable diazepam) but no currently available evidence concludes that IL is superior to diazepam in the management of pediatric status epilepticus." | 3.76 | [Use of injectable lorazepam in status epilepticus: a comparative study in French-speaking hospitals]. ( Auvin, S; Bourdon, O; Brion, F; Curatolo, N; Prot-Labarthe, S; Sachs, P, 2010) |
| "The authors convened concurrent focus groups of research staff and investigators involved in a pharmacokinetic study of lorazepam for status epilepticus (SE)." | 3.75 | Perceived challenges to obtaining informed consent for a time-sensitive emergency department study of pediatric status epilepticus: results of two focus groups. ( Baren, JM; Brown, KM; Chamberlain, JM; Davis, CO; Fawumi, O; Lillis, K; Nichols, S; Singh, T; Vance, C, 2009) |
| "A 44-year-old man with treated neurosyphilis presented with subclinical status epilepticus (SE) refractory to intravenous high-dose lorazepam, phenytoin, and valproic acid over 4 days." | 3.72 | Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. ( Lerner, AJ; Maddux, BN; Sagar, SM; Suarez, JI; Ubogu, EE; Werz, MA, 2003) |
| "The aim of this report is to describe the clinical and electroencephalographic findings seen in an elderly woman without previous history of seizures who developed a nonconvulsive generalized status epilepticus following acute withdrawal of lorazepam." | 3.71 | De novo absence status of late onset following withdrawal of lorazepam: a case report. ( Fernández-Torre, JL, 2001) |
| "Previous trials have suggested lorazepam may be superior to diazepam as first-line treatment of convulsive status epilepticus (CSE), with improved seizure outcome, and a lower incidence of side-effects." | 3.71 | A comparison of lorazepam and diazepam as initial therapy in convulsive status epilepticus. ( Cock, HR; Schapira, AH, 2002) |
| " Three cases of convulsive status epilepticus (CSE) following abrupt discontinuation of long-term use of 25 mg of lorazepam in one patient and more than 20 mg of flunitrazepam in two patients are presented; they were non-epileptics and free of other high-risk factors for seizures." | 3.70 | Convulsive status epilepticus following abrupt high-dose benzodiazepine discontinuation. ( Angelopoulos, EK; Chioni, A; Daskalopoulou, EG; Gatzonis, SD; Mantouvalos, V; Siafakas, A; Zournas, C, 2000) |
| "We treated nine refractory status epilepticus cases with high-dose intravenous lorazepam." | 3.69 | High-dose intravenous lorazepam for the treatment of refractory status epilepticus. ( Ali, A; Labar, DR; Root, J, 1994) |
| "A 19-year-old woman presented with status epilepticus and ventricular dysrhythmias less than one hour after ingesting 5,000 mg dimenhydrinate (Dramamine)." | 3.68 | Fatality secondary to massive overdose of dimenhydrinate. ( McDonnell, KP; Winn, RE, 1993) |
| "We studied the efficacy, pharmacokinetics, and brain entry of lorazepam in the treatment of status epilepticus (SE) using a rat model of secondarily generalized convulsive SE." | 3.68 | Lorazepam treatment of experimental status epilepticus in the rat: relevance to clinical practice. ( Treiman, DM; Walton, NY, 1990) |
| "Twenty-one episodes of status epilepticus (SE) were each treated with 1 to 9 mg (mean, 4 mg) of intravenous lorazepam." | 3.67 | Treatment of status epilepticus with lorazepam. ( Krall, RL; Levy, RJ, 1984) |
| "The drugs currently used in the emergency management of seizures are chiefly phenytoin, phenobarbital, diazepam, lorazepam, and paraldehyde." | 3.67 | Emergency management of seizures: an overview. ( Uthman, BM; Wilder, BJ, 1989) |
| "This report details the management of status epilepticus with high-dose lorazepam in a 14-year-old patient who was receiving oral clonazepam, ethosuximide, and phenobarbital for an intractable seizure disorder." | 3.67 | High-dose lorazepam therapy for status epilepticus in a pediatric patient. ( Gilmore, RL; Kuhn, RJ; Reincke, HM, 1988) |
| "We report our experience with 300 consecutive parenteral doses of lorazepam (LOR) for status epilepticus (SE) or serial seizures in 77 children and young adults." | 3.67 | Lorazepam in childhood status epilepticus and serial seizures: effectiveness and tachyphylaxis. ( Crawford, TO; Mitchell, WG; Snodgrass, SR, 1987) |
| "Lorazepam was most frequently administered intravenously in the emergency department, midazolam intramuscularly or intravenously by the emergency medical services personnel, and diazepam rectally prior to ambulance arrival." | 3.01 | Patterns of benzodiazepine underdosing in the Established Status Epilepticus Treatment Trial. ( Bleck, TP; Chamberlain, JM; Cloyd, JC; Cock, HR; Coles, LD; Conwit, RA; Elm, JJ; Fountain, NB; Kapur, J; Lowenstein, DH; Rosenthal, ES; Sathe, AG; Shinnar, S; Silbergleit, R; Underwood, E, 2021) |
| "Primary outcome was seizure cessation for 1h, and secondary outcomes were 24h seizure remission, in-hospital death, and severe adverse events (SAE)." | 2.84 | Comparison of lacosamide versus sodium valproate in status epilepticus: A pilot study. ( Dubey, D; Kalita, J; Misra, UK, 2017) |
| "Therefore, the acute care of prolonged seizures and SE is a constant challenge for healthcare professionals, in both the pre-hospital and the in-hospital settings." | 2.82 | Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability. ( Beuchat, I; Gelhard, S; Kay, L; Kienitz, R; Lucaciu, A; Mann, C; Rosenow, F; Schäfer, JH; Schubert-Bast, S; Siebenbrodt, K; Strzelczyk, A; von Brauchitsch, S; Willems, LM; Zöllner, JP, 2022) |
| "Diazepam rectal gel is an effective rescue therapy for seizure clusters, though adults and adolescents may have social reservations regarding its administration." | 2.82 | Rescue Treatments for Seizure Clusters. ( Gidal, BE; Kotloski, RJ, 2022) |
| "Lorazepam is likely to be a better therapy than diazepam." | 2.70 | A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. ( Alldredge, BK; Allen, F; Corry, MD; Gelb, AM; Gottwald, MD; Isaacs, SM; Lowenstein, DH; Neuhaus, JM; O'Neil, N; Segal, MR; Ulrich, S, 2001) |
| "Diazepam gel was better than placebo gel in reducing the risk of non-cessation of seizures (RR 0." | 2.50 | Anticonvulsant therapy for status epilepticus. ( Al-Roomi, K; Krishnan, PR; Prasad, M; Sequeira, R, 2014) |
| "Acute seizure and status epilepticus constitute one of the major medical emergencies in children." | 2.48 | Management of acute seizure and status epilepticus in pediatric emergency. ( Sasidaran, K; Singhi, P; Singhi, S, 2012) |
| "Current thinking about the acute treatment of status epilepticus (SE) emphasizes a more aggressive clinical approach to this common life-threatening neurologic emergency." | 2.45 | Emergency treatment of status epilepticus: current thinking. ( Millikan, D; Rice, B; Silbergleit, R, 2009) |
| "Status epilepticus is a neurological emergency requiring prompt pharmacological intervention." | 2.43 | Treatment options for status epilepticus. ( Lowenstein, DH, 2005) |
| "Status epilepticus is a major medical emergency associated with significant morbidity and mortality." | 2.42 | The management of status epilepticus. ( Marik, PE; Varon, J, 2004) |
| "Once SE is controlled, prevention of seizure recurrence should be individualized to each patient." | 2.40 | Management approaches to prolonged seizures and status epilepticus. ( Bleck, TP, 1999) |
| "Sequelae and risk for recurrence of SE are primarily related to the underlying cause." | 2.39 | Status epilepticus and acute repetitive seizures in children, adolescents, and young adults: etiology, outcome, and treatment. ( Mitchell, WG, 1996) |
| " Differences in pharmacokinetic parameters, therefore, will influence the choice of drug." | 2.38 | Pharmacokinetics and clinical use of benzodiazepines in the management of status epilepticus. ( Treiman, DM, 1989) |
| "Finally, seizure-like nonepileptic disorders were reviewed and differential diagnostic points highlighted." | 2.36 | Seizures and seizure-like states in the child: an approach to emergency management. ( Oppenheimer, EY; Rosman, NP, 1983) |
| " It has been shown that lorazepam is commonly under dosed in SE, but there is conflicting data on whether this has a negative impact on patient outcomes." | 1.91 | Evaluation of intravenous lorazepam dosing strategies and the incidence of refractory status epilepticus. ( Cetnarowski, A; Cunningham, B; Fowler, M; Mullen, C, 2023) |
| "Status Epilepticus is the most common non-traumatic neurologic emergency in childhood." | 1.72 | Resolution of status epilepticus after ketamine administration. ( Hakmeh, W; Howing, CE; Razi, F, 2022) |
| " Formulation and dosage of lorazepam were the same in both routes." | 1.62 | A Comparative Study on Intranasal Versus Intravenous Lorazepam in the Management of Acute Seizure in Children. ( Ghosh, T; Roy, UK; Rudra, N, 2021) |
| "8 %) the dosage was below the recommended level." | 1.62 | Recognition and treatment of status epilepticus in the prehospital setting. ( Bösel, J; Godau, J; Maier, S; Rösche, J, 2021) |
| " Risk factors for the disease include older age, renal dysfunction, critical illness, and inappropriate dosing based upon renal function." | 1.56 | Cefepime-Induced Neurotoxicity Presenting with Nonconvulsive Status Epilepticus Admitted as a Stroke Alert. ( Allyn, R; Cunningham, JM; Sachs, KV, 2020) |
| "Early recognition and treatment of seizures is essential for optimal patient outcomes." | 1.51 | Active Seizures in Children Are Often Subtle and Unrecognized by Prehospital Providers. ( Abramson, TM; Kearl, YL; Loza-Gomez, A; Rose, E, 2019) |
| " The most common adverse events (AEs) were somnolence (7." | 1.51 | [Efficacy and Safety of Lorazepam Intravenously Administered in Subjects with Status Epilepticus or Repetitive Seizures]. ( Nakasato, N; Nakazuru, Y; Ohtsuka, Y; Terada, M, 2019) |
| " Our objective was to evaluate BZD dosing in SE patients and its effects on clinical/electrographic outcomes." | 1.48 | Inadequate benzodiazepine dosing may result in progression to refractory and non-convulsive status epilepticus. ( Ibrahim, M; Mahulikar, A; Mohamed, W; Rao, SK; Seraji-Bozorgzad, N; Shah, A, 2018) |
| "Scrub typhus is an emerging infection, and there is little information about status epilepticus (SE) in scrub typhus." | 1.43 | Status epilepticus in scrub typhus. ( Bhoi, SK; Kalita, J; Mani, VE; Misra, UK, 2016) |
| "Status epilepticus was induced by intra-amygdala microinjection of kainic acid in 8week old C57Bl/6 mice." | 1.42 | Comparison of short-term effects of midazolam and lorazepam in the intra-amygdala kainic acid model of status epilepticus in mice. ( Diviney, M; Henshall, DC; Reynolds, JP, 2015) |
| "Pentobarbital was chosen later in the therapy for all ages." | 1.39 | Treatment of status epilepticus: an international survey of experts. ( Alldredge, B; Bell, R; Bleck, TP; Brophy, GM; Claassen, J; Glauser, T; LaRoche, SM; Riviello, JJ; Shutter, L; Sperling, MR; Treiman, DM; Vespa, PM, 2013) |
| "Prolonged seizures [status epilepticus (SE)] constitute a neurological emergency that can permanently damage the brain." | 1.38 | Seizure suppression and neuroprotection by targeting the purinergic P2X7 receptor during status epilepticus in mice. ( Diaz-Hernandez, M; Engel, T; Garcia-Huerta, P; Gomez-Villafuertes, R; Henshall, DC; Mesuret, G; Miras-Portugal, MT; Sanz-Rodriguez, A; Tanaka, K, 2012) |
| "Subacute encephalopathy with seizures in chronic alcoholism (SESA) was first described in 1981 by Niedermeyer who reported alcoholic patients presenting with confusion, seizures and focal neurological deficits and is quite distinct from patients presenting with typical alcohol withdrawal seizures." | 1.37 | Subacute encephalopathy and seizures in alcoholics (SESA) presenting with non-convulsive status epilepticus. ( LaRoche, SM; Shivdat-Nanhoe, R, 2011) |
| "In a patient with SIRPIDs, aphasia and confusion, i." | 1.37 | Confusion and SIRPIDs regress with parenteral lorazepam. ( Duckworth, J; Kaplan, PW, 2011) |
| "Of patients with status epilepticus and central nervous system infection, 24." | 1.35 | Status epilepticus in central nervous system infections: an experience from a developing country. ( Kalita, J; Misra, UK; Nair, PP, 2008) |
| " Measurement of serum concentrations and changes in dosing guidelines can probably prevent NCSE during cefepime therapy." | 1.33 | Nonconvulsive status epilepticus due to cefepime in a patient with normal renal function. ( Biswas, A; Jolin, D; Maganti, R; Rishi, D, 2006) |
| "Any prolonged cognitive alterations or confusional states may have additional causes and require extensive diagnostic effort." | 1.33 | Prolonged confusional state following electroconvulsive therapy--diagnostic clues from serial electroencephalography. ( Ehrentraut, S; Hegerl, U; Henkel, V; Möller, HJ; Mulert, C; Pogarell, O; Rüther, T, 2005) |
| "Diazepam rectal gel was given more quickly and reliably, reducing total seizure time, potential neuronal injury and other complications." | 1.32 | Treatment of out-of-hospital status epilepticus with diazepam rectal gel. ( Fitzgerald, BJ; Miller, JW; Okos, AJ, 2003) |
| "Lorazepam appears to be an effective and safe drug for treatment of status epilepticus, with a duration of control longer than that achieved with diazepam." | 1.26 | Lorazepam in status epilepticus. ( Bell, RD; Crawford, IL; Homan, RW; Tasker, WG; Vasko, MR; Walker, JE, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (15.03) | 18.7374 |
| 1990's | 17 (11.11) | 18.2507 |
| 2000's | 38 (24.84) | 29.6817 |
| 2010's | 56 (36.60) | 24.3611 |
| 2020's | 19 (12.42) | 2.80 |
| Authors | Studies |
|---|---|
| Howing, CE | 1 |
| Razi, F | 1 |
| Hakmeh, W | 1 |
| Guterman, EL | 2 |
| Burke, JF | 2 |
| Sporer, KA | 1 |
| Cruickshank, M | 1 |
| Imamura, M | 1 |
| Counsell, C | 1 |
| Aucott, L | 1 |
| Manson, P | 1 |
| Booth, C | 1 |
| Scotland, G | 1 |
| Brazzelli, M | 1 |
| Hasan, SU | 1 |
| Pervez, A | 1 |
| Bhatty, S | 1 |
| Shamim, S | 1 |
| Naeem, A | 1 |
| Naseeb, MW | 1 |
| Gawedzki, P | 1 |
| Celmins, L | 1 |
| Fischer, D | 1 |
| Rudra, N | 1 |
| Ghosh, T | 1 |
| Roy, UK | 1 |
| Kienitz, R | 1 |
| Kay, L | 1 |
| Beuchat, I | 1 |
| Gelhard, S | 1 |
| von Brauchitsch, S | 1 |
| Mann, C | 1 |
| Lucaciu, A | 1 |
| Schäfer, JH | 1 |
| Siebenbrodt, K | 1 |
| Zöllner, JP | 1 |
| Schubert-Bast, S | 1 |
| Rosenow, F | 2 |
| Strzelczyk, A | 1 |
| Willems, LM | 1 |
| Sherman, NA | 1 |
| Silbergleit, R | 8 |
| Bengelink, EM | 1 |
| Durkalski, V | 5 |
| Wolter, KD | 1 |
| Kotloski, RJ | 1 |
| Gidal, BE | 1 |
| Cetnarowski, A | 1 |
| Cunningham, B | 1 |
| Mullen, C | 1 |
| Fowler, M | 1 |
| Lelis, IR | 1 |
| Krauss, GL | 1 |
| Garcia-Durillo, M | 1 |
| Frenguelli, BG | 1 |
| Rose, E | 1 |
| Abramson, TM | 1 |
| Kearl, YL | 1 |
| Loza-Gomez, A | 1 |
| Walters, E | 1 |
| Wurster Ovalle, V | 1 |
| Yin, S | 1 |
| Dribin, T | 1 |
| Cunningham, JM | 1 |
| Sachs, KV | 1 |
| Allyn, R | 1 |
| Taymouri, S | 1 |
| Minaiyan, M | 1 |
| Ebrahimi, F | 1 |
| Tavakoli, N | 1 |
| Kamdar, HA | 1 |
| Hamed, M | 1 |
| Smetana, KS | 1 |
| Shanmugam, K | 1 |
| Peters, E | 1 |
| Yasin, R | 1 |
| Thakur, G | 1 |
| Gopal, M | 1 |
| Sawalha, K | 1 |
| Greene-Chandos, D | 1 |
| Hussein, O | 1 |
| Han, EJ | 1 |
| Chuck, CC | 1 |
| Martin, TJ | 1 |
| Madsen, TE | 1 |
| Claassen, J | 3 |
| Reznik, ME | 1 |
| Maier, S | 1 |
| Godau, J | 1 |
| Bösel, J | 1 |
| Rösche, J | 1 |
| Sathe, AG | 1 |
| Underwood, E | 1 |
| Coles, LD | 1 |
| Elm, JJ | 1 |
| Chamberlain, JM | 6 |
| Kapur, J | 1 |
| Cock, HR | 2 |
| Fountain, NB | 1 |
| Shinnar, S | 1 |
| Lowenstein, DH | 6 |
| Rosenthal, ES | 1 |
| Conwit, RA | 1 |
| Bleck, TP | 4 |
| Cloyd, JC | 2 |
| Johnson, PN | 1 |
| Nguyen, A | 1 |
| Neely, SB | 1 |
| Johnson, M | 1 |
| Brigo, F | 2 |
| Trinka, E | 3 |
| Misra, UK | 5 |
| Dubey, D | 1 |
| Kalita, J | 5 |
| McTague, A | 1 |
| Martland, T | 2 |
| Appleton, R | 3 |
| Rao, SK | 1 |
| Mahulikar, A | 1 |
| Ibrahim, M | 1 |
| Shah, A | 1 |
| Seraji-Bozorgzad, N | 1 |
| Mohamed, W | 1 |
| Ku, LC | 1 |
| Hornik, CP | 1 |
| Beechinor, RJ | 1 |
| Guptill, JT | 1 |
| Harper, B | 1 |
| Capparelli, EV | 2 |
| Martz, K | 1 |
| Anand, R | 1 |
| Cohen-Wolkowiez, M | 1 |
| Gonzalez, D | 1 |
| Caraballo, RH | 1 |
| Chacón, S | 1 |
| Fasulo, L | 1 |
| Bedoya, C | 1 |
| Nene, D | 1 |
| Mundlamuri, RC | 2 |
| Satishchandra, P | 2 |
| Prathyusha, PV | 2 |
| Nagappa, M | 2 |
| Bindu, PS | 2 |
| Raghavendra, K | 1 |
| Saini, J | 1 |
| Bharath, RD | 1 |
| Thennarasu, K | 1 |
| Taly, AB | 2 |
| Sinha, S | 2 |
| Betjemann, JP | 1 |
| Josephson, SA | 1 |
| Ohtsuka, Y | 1 |
| Nakasato, N | 1 |
| Nakazuru, Y | 1 |
| Terada, M | 1 |
| Owusu, KA | 1 |
| Dhakar, MB | 1 |
| Bautista, C | 1 |
| McKimmy, D | 1 |
| Cotugno, S | 1 |
| Sukumar, N | 1 |
| Deng, Y | 1 |
| Farooque, P | 2 |
| Hirsch, LJ | 2 |
| Maciel, CB | 1 |
| Burns, JM | 1 |
| Marino, A | 1 |
| Manno, M | 1 |
| Rhyee, S | 1 |
| Boyer, EW | 1 |
| Sharma, D | 1 |
| Maheshwari, D | 1 |
| Philip, G | 1 |
| Rana, R | 1 |
| Bhatia, S | 1 |
| Singh, M | 1 |
| Gabrani, R | 1 |
| Sharma, SK | 1 |
| Ali, J | 1 |
| Sharma, RK | 1 |
| Dang, S | 1 |
| Poulton, A | 1 |
| Rai, DK | 1 |
| Venter, K | 1 |
| Clemons, T | 1 |
| Prasad, M | 1 |
| Krishnan, PR | 3 |
| Sequeira, R | 3 |
| Al-Roomi, K | 3 |
| Welch, RD | 1 |
| Nicholas, K | 1 |
| Durkalski-Mauldin, VL | 1 |
| Conwit, R | 3 |
| Mahajan, PV | 1 |
| Lewandowski, C | 1 |
| Meurer, WJ | 1 |
| Nicholas, KS | 1 |
| Goldstein, JN | 1 |
| Fu, R | 1 |
| Subbakrishna, DK | 1 |
| Umamaheswara Rao, GS | 1 |
| Alvarez, V | 1 |
| Lee, JW | 1 |
| Drislane, FW | 1 |
| Westover, MB | 1 |
| Novy, J | 1 |
| Dworetzky, BA | 1 |
| Rossetti, AO | 2 |
| Pinto, RF | 1 |
| Turnbull, J | 1 |
| Diviney, M | 1 |
| Reynolds, JP | 1 |
| Henshall, DC | 2 |
| Kellinghaus, C | 1 |
| Lang, N | 1 |
| Rüegg, S | 1 |
| Tilz, C | 1 |
| Unterberger, I | 1 |
| Uzelac, Z | 1 |
| Zhao, ZY | 1 |
| Wang, HY | 1 |
| Wen, B | 1 |
| Yang, ZB | 1 |
| Feng, K | 1 |
| Fan, JC | 1 |
| Wu, W | 1 |
| Zhang, L | 1 |
| Xue, R | 1 |
| Mani, VE | 1 |
| Bhoi, SK | 1 |
| Gersner, R | 1 |
| Dhamne, SC | 1 |
| Zangen, A | 1 |
| Pascual-Leone, A | 1 |
| Rotenberg, A | 1 |
| Bragazzi, NL | 1 |
| Bacigaluppi, S | 1 |
| Nardone, R | 1 |
| Chamberlain, DB | 1 |
| Nair, PP | 1 |
| Kriel, RL | 1 |
| Millikan, D | 1 |
| Rice, B | 1 |
| Sperli, F | 1 |
| Placidi, F | 1 |
| Izzi, F | 1 |
| Marciani, MG | 1 |
| Floris, R | 1 |
| Ludovici, A | 1 |
| Cervellino, A | 1 |
| Torelli, F | 1 |
| Romigi, A | 1 |
| Konieczny, PL | 1 |
| Reimer, R | 1 |
| Sreenath, TG | 1 |
| Gupta, P | 1 |
| Sharma, KK | 1 |
| Krishnamurthy, S | 1 |
| Wheless, JW | 2 |
| Lillis, K | 2 |
| Vance, C | 1 |
| Brown, KM | 2 |
| Fawumi, O | 1 |
| Nichols, S | 1 |
| Davis, CO | 2 |
| Singh, T | 1 |
| Baren, JM | 2 |
| Zhao, W | 1 |
| Pauls, K | 1 |
| Dillon, C | 1 |
| Kim, J | 1 |
| Kolk, D | 1 |
| Stevenson, V | 1 |
| Palesch, Y | 2 |
| Curatolo, N | 1 |
| Prot-Labarthe, S | 1 |
| Auvin, S | 1 |
| Sachs, P | 1 |
| Brion, F | 1 |
| Bourdon, O | 1 |
| Khurana, DS | 1 |
| Melvin, JJ | 1 |
| Okazaki, K | 1 |
| Kondo, M | 1 |
| Kubota, M | 1 |
| Kakinuma, R | 1 |
| Hoshino, A | 1 |
| Kimura, H | 1 |
| Itoh, S | 1 |
| Anderson, M | 1 |
| Al-Khamees, WA | 1 |
| Schwartz, MD | 1 |
| Alrashdi, S | 1 |
| Algren, AD | 1 |
| Morgan, BW | 1 |
| LaRoche, SM | 2 |
| Shivdat-Nanhoe, R | 1 |
| Sokolova, EIu | 1 |
| Savin, IA | 1 |
| Lubnin, AIu | 1 |
| Maurya, PK | 1 |
| Kaplan, PW | 2 |
| Duckworth, J | 1 |
| de Monteverde-Robb, DJ | 1 |
| Allen, CM | 1 |
| Damian, MS | 1 |
| Manford, MR | 1 |
| Burnstein, RM | 1 |
| Gunning, KE | 1 |
| Menon, DK | 1 |
| Lowenstein, D | 2 |
| Ko, SB | 1 |
| Ortega-Gutierrez, S | 1 |
| Choi, HA | 1 |
| Presciutti, M | 1 |
| Schmidt, JM | 1 |
| Badjatia, N | 1 |
| Lee, K | 1 |
| Mayer, SA | 1 |
| Vance, CW | 1 |
| Mahajan, P | 1 |
| Lichenstein, R | 1 |
| Stanley, RM | 1 |
| Gordon, S | 1 |
| van den Anker, JN | 1 |
| Sasidaran, K | 1 |
| Singhi, S | 1 |
| Singhi, P | 1 |
| Engel, T | 1 |
| Gomez-Villafuertes, R | 1 |
| Tanaka, K | 1 |
| Mesuret, G | 1 |
| Sanz-Rodriguez, A | 1 |
| Garcia-Huerta, P | 1 |
| Miras-Portugal, MT | 1 |
| Diaz-Hernandez, M | 1 |
| Pancioli, A | 1 |
| Barsan, W | 1 |
| Pittermann, P | 1 |
| Gabriel, S | 1 |
| Röschke, J | 1 |
| Galimi, R | 1 |
| Xue, FS | 1 |
| Liao, X | 1 |
| Cheng, Y | 1 |
| Asmussen, S | 1 |
| Maybauer, DM | 1 |
| Maybauer, MO | 1 |
| Riviello, JJ | 1 |
| Sperling, MR | 1 |
| Alldredge, B | 1 |
| Glauser, T | 1 |
| Shutter, L | 1 |
| Treiman, DM | 7 |
| Vespa, PM | 1 |
| Bell, R | 1 |
| Brophy, GM | 1 |
| Fitzgerald, BJ | 1 |
| Okos, AJ | 1 |
| Miller, JW | 1 |
| Phillips, B | 1 |
| Ubogu, EE | 1 |
| Sagar, SM | 1 |
| Lerner, AJ | 1 |
| Maddux, BN | 1 |
| Suarez, JI | 1 |
| Werz, MA | 1 |
| Marik, PE | 1 |
| Varon, J | 1 |
| Walker, M | 1 |
| Prasad, K | 2 |
| Maganti, R | 1 |
| Jolin, D | 1 |
| Rishi, D | 1 |
| Biswas, A | 1 |
| Malmgren, K | 1 |
| Pogarell, O | 1 |
| Ehrentraut, S | 1 |
| Rüther, T | 1 |
| Mulert, C | 1 |
| Hegerl, U | 1 |
| Möller, HJ | 1 |
| Henkel, V | 1 |
| Kälviäinen, R | 1 |
| Autti-Rämö, I | 1 |
| Eriksson, K | 1 |
| Häppölä, O | 1 |
| Keränen, T | 1 |
| Kuoppala, J | 1 |
| Kurola, J | 1 |
| Kuusela, AL | 1 |
| Mervaala, E | 1 |
| Salmi, T | 1 |
| Tallgren, M | 1 |
| Choudhery, V | 1 |
| Townend, W | 1 |
| Minicucci, F | 1 |
| Muscas, G | 1 |
| Perucca, E | 1 |
| Capovilla, G | 1 |
| Vigevano, F | 1 |
| Tinuper, P | 1 |
| Deshpande, LS | 1 |
| Blair, RE | 1 |
| Nagarkatti, N | 1 |
| Sombati, S | 1 |
| Martin, BR | 1 |
| DeLorenzo, RJ | 1 |
| Delima, SI | 1 |
| Walsh, LE | 1 |
| Golomb, MR | 1 |
| Jackson, MJ | 1 |
| Dardis, C | 1 |
| Farid, S | 1 |
| Doherty, C | 1 |
| Griffith, PA | 1 |
| Karp, HR | 1 |
| Sorel, L | 2 |
| Mechler, L | 2 |
| Harmant, J | 2 |
| Leppik, IE | 1 |
| Derivan, AT | 1 |
| Homan, RW | 3 |
| Walker, J | 1 |
| Ramsay, RE | 2 |
| Patrick, B | 1 |
| Walker, JE | 2 |
| Oppenheimer, EY | 1 |
| Rosman, NP | 1 |
| Levy, RJ | 1 |
| Krall, RL | 1 |
| Browne, TR | 1 |
| Delgado-Escueta, AV | 1 |
| Wasterlain, C | 1 |
| Porter, RJ | 1 |
| Sweeney, A | 1 |
| Choonara, I | 1 |
| Robson, J | 1 |
| Molyneux, E | 1 |
| Jagoda, A | 1 |
| Riggio, S | 1 |
| Fink, M | 1 |
| Labar, DR | 1 |
| Ali, A | 1 |
| Root, J | 1 |
| Winn, RE | 1 |
| McDonnell, KP | 1 |
| Terndrup, TE | 1 |
| Paskanik, AM | 1 |
| Fordyce, WE | 1 |
| Kanter, RK | 1 |
| Mitchell, WG | 2 |
| Jiang, Q | 1 |
| Walton, NY | 3 |
| Gunawan, S | 2 |
| Lukovits, TG | 1 |
| Fadul, CE | 1 |
| Pipas, JM | 1 |
| Williamson, PD | 1 |
| Thibodeau, LG | 1 |
| Ferrera, PC | 1 |
| Meyers, PD | 1 |
| Collins, JF | 1 |
| Colling, C | 1 |
| Rowan, AJ | 1 |
| Handforth, A | 1 |
| Faught, E | 1 |
| Calabrese, VP | 1 |
| Uthman, BM | 2 |
| Mamdani, MB | 1 |
| Johnson, KH | 1 |
| Caton, H | 1 |
| Gatzonis, SD | 1 |
| Angelopoulos, EK | 1 |
| Daskalopoulou, EG | 1 |
| Mantouvalos, V | 1 |
| Chioni, A | 1 |
| Zournas, C | 1 |
| Siafakas, A | 1 |
| Butler, J | 1 |
| Lewis, M | 1 |
| Alldredge, BK | 1 |
| Gelb, AM | 1 |
| Isaacs, SM | 1 |
| Corry, MD | 1 |
| Allen, F | 1 |
| Ulrich, S | 1 |
| Gottwald, MD | 1 |
| O'Neil, N | 1 |
| Neuhaus, JM | 1 |
| Segal, MR | 1 |
| Valenzuela, TD | 1 |
| Copass, MK | 1 |
| Larkin, M | 1 |
| Fernández-Torre, JL | 1 |
| Su, M | 1 |
| Chodosh, A | 1 |
| Nelson, LS | 1 |
| Lockey, AS | 1 |
| Morgan, S | 1 |
| Schapira, AH | 1 |
| Qureshi, A | 1 |
| Wassmer, E | 1 |
| Davies, P | 1 |
| Berry, K | 1 |
| Whitehouse, WP | 1 |
| Brouns, R | 1 |
| Van Paesschen, W | 1 |
| Vasko, MR | 1 |
| Crawford, IL | 1 |
| Bell, RD | 1 |
| Tasker, WG | 1 |
| Mar Molinero, F | 1 |
| Sánchez Díaz, JI | 1 |
| Torres Mohedas, J | 1 |
| Wilder, BJ | 1 |
| Lacey, DJ | 2 |
| Singer, WD | 1 |
| Horwitz, SJ | 1 |
| Gilmore, H | 1 |
| Reincke, HM | 1 |
| Gilmore, RL | 1 |
| Kuhn, RJ | 1 |
| Celesia, GG | 1 |
| Grigg, MM | 1 |
| Ross, E | 1 |
| Laborde, A | 1 |
| Nogué, S | 1 |
| Munné, P | 1 |
| Graus, F | 1 |
| Haigh, JR | 1 |
| Feely, MP | 1 |
| Crawford, TO | 1 |
| Snodgrass, SR | 1 |
| Vincent, FM | 1 |
| Vincent, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-blind Randomized Clinical Trial of the Efficacy of IM Midazolam Versus IV Lorazepam in the Pre-hospital Treatment of Status Epilepticus by Paramedics[NCT00809146] | Phase 3 | 1,023 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| A Multicenter, Randomized, Blinded, Comparative Effectiveness Study of Fosphenytoin, Valproic Acid, or Levetiracetam in the Emergency Department Treatment of Patients With Benzodiazepine-refractory Status Epilepticus.[NCT01960075] | Phase 3 | 478 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| Use Of Lorazepam For The Treatment Of Pediatric Status Epilepticus: A Randomized, Double-Blinded Trial Of Lorazepam And Diazepam[NCT00621478] | Phase 2/Phase 3 | 259 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Effectiveness of Combined Levetiracetam and Midazolam in Treatment of Generalized Convulsive Status Epilepticus in Children[NCT04926844] | Phase 2 | 144 participants (Actual) | Interventional | 2021-06-20 | Completed | ||
| A Pilot Study to Assess the Efficacy of Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy[NCT05019885] | Phase 2 | 6 participants (Anticipated) | Interventional | 2022-08-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Continuous acute care inpatient hospital days from day of admission until discharge (NCT00809146)
Timeframe: participants were followed for the duration of hospital stay, an average of 6 days
| Intervention | days (Mean) |
|---|---|
| IM Midazolam | 6.7 |
| IV Lorazepam | 5.5 |
Continuous days of initial ICU stay from time of admission (NCT00809146)
Timeframe: participants were followed for the duration of hospital stay, an average of 6 days
| Intervention | days (Mean) |
|---|---|
| IM Midazolam | 5.7 |
| IV Lorazepam | 4.1 |
Hospital and ICU admission from the ED, and length of stay, is abstracted from the hospital admission record. ICU admission is recorded as occurring only if the ICU is the initial inpatient unit for the patient. (NCT00809146)
Timeframe: at time of disposition on day of enrollment
| Intervention | participants (Number) |
|---|---|
| IM Midazolam | 128 |
| IV Lorazepam | 161 |
Hospital and ICU admission from the ED, and length of stay, is abstracted from the hospital admission record. ICU admission is recorded as occurring only if the ICU is the initial inpatient unit for the patient. (NCT00809146)
Timeframe: at ED disposition on day of enrollment
| Intervention | participants (Number) |
|---|---|
| IM Midazolam | 258 |
| IV Lorazepam | 292 |
Endotracheal intubation performed or attempted by EMS or within 30 minutes after ED arrival is abstracted from the ED record physician and nursing records. Endotracheal intubation includes placement of a definitive tracheal airway (oro-, naso-, cricothyroidotomy, or tracheostomy) for support of respirations or protection of airway. Non-definitive and/or non-tracheal airways (oral or nasal airways, laryngeal mask airways, or esophageal obturator airways) are not included if the patient is not subsequently intubated unless specifically deemed to have been used in lieu of tracheal intubation. (NCT00809146)
Timeframe: anytime before 30 minutes after ED arrival
| Intervention | participants (Number) |
|---|---|
| IM Midazolam | 63 |
| IV Lorazepam | 64 |
Acute hypotension is defined as a systolic blood pressure of < 90 mmHg sustained for greater than 5 minutes and for which the patient was treated with a continuous IV infusion of a vasopressor. (NCT00809146)
Timeframe: participants were followed for the duration of hospital stay, an average of 6 days
| Intervention | participants (Number) |
|---|---|
| IM Midazolam | 12 |
| IV Lorazepam | 13 |
IM injection site complications are defined as any symptoms or signs of injury or reaction at the site of the study IM injection requiring treatment. This includes extensive hematoma requiring treatment (decompression, pressure dressings, or discontinuation of anticoagulant or antithrombotic medications). Treatment does not include imaging without other interventions. This definition also includes wound infection requiring antibiotic therapy, retained foreign bodies requiring exploration and removal, or other similar wound problems. (NCT00809146)
Timeframe: participants were followed for the duration of hospital stay, an average of 6 days
| Intervention | participants (Number) |
|---|---|
| IM Midazolam | 4 |
| IV Lorazepam | 2 |
IV insertion site complications are defined as any symptoms or signs of injury or reaction at the site of the study IV placed by paramedics and used for study medication. This includes thrombosis, phlebitis, or skin infection requiring specific treatment including compresses, antibiotics, or wound care. (NCT00809146)
Timeframe: participants were followed for the duration of hospital stay, an average of 6 days
| Intervention | participants (Number) |
|---|---|
| IM Midazolam | 0 |
| IV Lorazepam | 3 |
Acute seizure recurrence is defined as any further convulsive or electrographic seizures occurring in the first 12 hours of hospitalization, if they require additional antiepileptic medications, in subjects that had been determined not to be having seizures on ED arrival. (NCT00809146)
Timeframe: within 12 hours after ED arrival
| Intervention | participants (Number) |
|---|---|
| IM Midazolam | 51 |
| IV Lorazepam | 47 |
The primary outcome was termination of seizures before arrival in the emergency department (ED) without the need for the paramedics to provide rescue therapy. Subjects did not reach the primary outcome if they were having seizures on arrival in the emergency department or if they received rescue medication before arrival. Termination of seizures on arrival was determined according to the clinical judgment of the attending emergency physician and was based on examination of the subjects, their clinical course, and results of any routine diagnostic testing. (NCT00809146)
Timeframe: Duration of prehospital care, outcome is determined upon arrival at the ED on the day of enrollment (average 20 minutes).
| Intervention | participants (Number) |
|---|---|
| IM Midazolam | 329 |
| IV Lorazepam | 282 |
Length of hospital stay in days (NCT01960075)
Timeframe: length of hospital stay
| Intervention | days (Median) |
|---|---|
| Fosphenytoin (FOS) | 3 |
| Valproic Acid | 3 |
| Levetiracetam | 3 |
Length of stay is determined by the number of calendar days after the day of ED arrival until hospital discharge or subject end-of-study. (NCT01960075)
Timeframe: number of calendar days after the day of ED arrival until hospital discharge or subject end-of-study
| Intervention | days (Median) |
|---|---|
| Fosphenytoin (FOS) | 1 |
| Valproic Acid | 1 |
| Levetiracetam | 1 |
The time to termination of seizures is the interval from the start of study drug infusion to cessation of clinically apparent seizure in those who meet the primary outcome. (NCT01960075)
Timeframe: start of drug infusion to seizure cessation
| Intervention | minutes (Median) |
|---|---|
| Fosphenytoin (FOS) | 11.7 |
| Valproic Acid | 7.0 |
| Levetiracetam | 10.5 |
ICU admission is recorded as occurring only if the ICU is the initial inpatient unit for the patient. (NCT01960075)
Timeframe: Admission to intensive care unit after start of study drug infusion, where the ICU is the initial inpatient unit for the patient
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 70 |
| Valproic Acid | 71 |
| Levetiracetam | 87 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. The Adjudicated outcomes analysis is different from Outcome measure 1 because a central clinical phenomenology core of four neurologists adjudicated from the medical records the time to seizure cessation, the time in status epilepticus before trial-drug initiation, and the cause of the seizure. For each enrollment, two neurologists from this core group conducted independent initial reviews and then determined a consensus or consulted a third adjudicator, as needed. Adjudicators were unaware of the treatment assignments and made determinations by medical record review. (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 57 |
| Valproic Acid | 60 |
| Levetiracetam | 67 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. Intention to treat (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 53 |
| Valproic Acid | 56 |
| Levetiracetam | 68 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. Per-protocol analysis (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 37 |
| Valproic Acid | 43 |
| Levetiracetam | 51 |
Acute anaphylaxis is defined as a clinical presentation consistent with life threatening allergic reaction occurring within 6 hours of the start of study drug infusions and manifested as urticaria in combination with either (1) a systolic blood pressure of < 90 mmHg sustained for greater than 5 minutes, or (2) objective evidence of airway obstruction, and for which the patient was treated with antihistamines and/or steroids. (NCT01960075)
Timeframe: within 6 hours of the start of study drug infusions
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 0 |
Respiratory depression is defined as impairment of ventilation or oxygenation necessitating definitive endotracheal intubation and mechanical ventilation. It is distinct from intubations performed only for airway protection in those with decreased levels of consciousness. It does not include those getting only supraglottic airways or transient bag-valve-mask support. (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 16 |
| Valproic Acid | 10 |
| Levetiracetam | 12 |
acute seizure recurrence 60 minutes to 12 hours after start of study drug infusion (NCT01960075)
Timeframe: 60 minutes to 12 hours after start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 14 |
| Valproic Acid | 14 |
| Levetiracetam | 16 |
Safety outcome: Death (NCT01960075)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 3 |
| Valproic Acid | 2 |
| Levetiracetam | 7 |
Endotracheal intubation within 60 minutes of start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 33 |
| Valproic Acid | 21 |
| Levetiracetam | 30 |
Safety outcome: Hepatic transaminase or ammonia elevations (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 1 |
| Levetiracetam | 1 |
Life-threatening hypotension within 60 minutes of the start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 4 |
| Valproic Acid | 2 |
| Levetiracetam | 1 |
Life-threatening cardiac arrhythmia within 60 minutes of the start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 1 |
Purple glove syndrome is defined as the presence of all three of the findings of the objective edema: discoloration, and pain in the distal extremity in which study drug was administered, with or without known extravasation, and for which there is no other evident etiology. (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 0 |
Number of participants with seizure cessation within 20 minutes of study drug initiation for patients with treatment success. This outcome measure was only reported in the Supplementary materials to the Primary Paper. (NCT01960075)
Timeframe: within 20 minutes
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 43 |
| Valproic Acid | 43 |
| Levetiracetam | 53 |
31 reviews available for lorazepam and Status Epilepticus
| Article | Year |
|---|---|
Management of the first stage of convulsive status epilepticus in adults: a systematic review of current randomised evidence.
Topics: Adult; Anticonvulsants; Diazepam; Humans; Lorazepam; Midazolam; Seizures; Status Epilepticus | 2022 |
Termination of seizures in the paediatric age group, best benzodiazepine and route of administration: A network meta-analysis.
Topics: Anticonvulsants; Benzodiazepines; Child; Diazepam; Humans; Lorazepam; Midazolam; Network Meta-Analys | 2022 |
Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability.
Topics: Anticonvulsants; Benzodiazepines; Clonazepam; Diazepam; gamma-Aminobutyric Acid; Humans; Lorazepam; | 2022 |
Rescue Treatments for Seizure Clusters.
Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Diazepam; Humans; Lorazepam; Midazolam; Nasal S | 2022 |
Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children.
Topics: Administration, Inhalation; Administration, Oral; Administration, Rectal; Anticonvulsants; Child; Di | 2018 |
Anticonvulsant therapy for status epilepticus.
Topics: Anticonvulsants; Diazepam; Humans; Injections, Intravenous; Lorazepam; Midazolam; Phenobarbital; Phe | 2014 |
A Comparison of Midazolam, Lorazepam, and Diazepam for the Treatment of Status Epilepticus in Children: A Network Meta-analysis.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Diazepam; Humans; Infant; Lorazepam; Mi | 2016 |
Lorazepam or diazepam for convulsive status epilepticus: A meta-analysis.
Topics: Anticonvulsants; Diazepam; Humans; Lorazepam; Seizures; Status Epilepticus; Treatment Outcome | 2016 |
Is intravenous lorazepam really more effective and safe than intravenous diazepam as first-line treatment for convulsive status epilepticus? A systematic review with meta-analysis of randomized controlled trials.
Topics: Administration, Intravenous; Anticonvulsants; Diazepam; Humans; Lorazepam; Randomized Controlled Tri | 2016 |
Emergency treatment of status epilepticus: current thinking.
Topics: Anesthesia, General; Anticonvulsants; Benzodiazepines; Electroencephalography; Emergency Medical Ser | 2009 |
Treatment of status epilepticus in children.
Topics: Anticonvulsants; Child; Child, Preschool; Diazepam; Drug Administration Schedule; Drug Therapy, Comb | 2004 |
Benzodiazepines for prolonged seizures.
Topics: Anticonvulsants; Benzodiazepines; Child, Preschool; Diazepam; Humans; Infant; Lorazepam; Midazolam; | 2010 |
[Non-convulsive epileptic status].
Topics: Anticonvulsants; Diagnosis, Differential; Electroencephalography; Humans; Lorazepam; Midazolam; Stat | 2011 |
Management of acute seizure and status epilepticus in pediatric emergency.
Topics: Anesthesia, Intravenous; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Combined Modalit | 2012 |
Nonconvulsive status epilepticus in pediatric populations: diagnosis and management.
Topics: Acetazolamide; Anticonvulsants; Benzodiazepines; Child; Clobazam; Electroencephalography; Humans; Lo | 2012 |
Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children.
Topics: Administration, Rectal; Anticonvulsants; Child; Diazepam; Epilepsy, Tonic-Clonic; Humans; Injections | 2002 |
Acute management of seizures in the syndromes of idiopathic generalized epilepsies.
Topics: Acute Disease; Adolescent; Adult; Anticonvulsants; Clonazepam; Comorbidity; Drug Administration Sche | 2003 |
The management of status epilepticus.
Topics: Anticonvulsants; Humans; Lorazepam; Midazolam; Propofol; Status Epilepticus | 2004 |
Treatment options for status epilepticus.
Topics: Adult; Animals; Anticonvulsants; GABA Modulators; Half-Life; Humans; Lorazepam; Meta-Analysis as Top | 2005 |
Status epilepticus: an evidence based guide.
Topics: Anticonvulsants; Chronic Disease; Critical Care; Drug Administration Routes; Emergency Treatment; Ev | 2005 |
Anticonvulsant therapy for status epilepticus.
Topics: Anticonvulsants; Diazepam; Humans; Lorazepam; Midazolam; Phenobarbital; Phenytoin; Randomized Contro | 2005 |
[Update on current care guidelines. Prolonged epileptic attack].
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Diazepam; Drug Therapy, Combination; El | 2006 |
Best evidence topic reports. Lorazepam or diazepam in paediatric status epilepticus.
Topics: Anticonvulsants; Child, Preschool; Diazepam; Evidence-Based Medicine; Female; Humans; Infusions, Int | 2006 |
Anticonvulsant therapy for status epilepticus.
Topics: Anticonvulsants; Diazepam; Humans; Lorazepam; Midazolam; Phenobarbital; Phenytoin; Randomized Contro | 2007 |
Seizures and seizure-like states in the child: an approach to emergency management.
Topics: Anesthesia, General; Child; Child, Preschool; Diagnosis, Differential; Diazepam; Emergencies; Humans | 1983 |
Therapy for status epilepticus.
Topics: Acetazolamide; Anesthesia; Anticonvulsants; Barbiturates; Chlormethiazole; Clonazepam; Diazepam; Eth | 1983 |
Status epilepticus and acute repetitive seizures in children, adolescents, and young adults: etiology, outcome, and treatment.
Topics: Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Benzodiazepines; Central Nervous System Disea | 1996 |
Management approaches to prolonged seizures and status epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Diazepam; Drug Administration Schedule; Drug Therapy, Combination; | 1999 |
Emergency department drug therapy for status epilepticus in adults.
Topics: Adult; Benzodiazepines; Emergency Service, Hospital; Humans; Hypnotics and Sedatives; Lorazepam; Phe | 2002 |
Pharmacokinetics and clinical use of benzodiazepines in the management of status epilepticus.
Topics: Benzodiazepines; Chemical Phenomena; Chemistry; Clonazepam; Diazepam; Humans; Lorazepam; Status Epil | 1989 |
Status epilepticus in children and adults.
Topics: Adult; Anticonvulsants; Child; Diazepam; Drug Therapy, Combination; Humans; Infusions, Intravenous; | 1988 |
19 trials available for lorazepam and Status Epilepticus
| Article | Year |
|---|---|
Patterns of benzodiazepine underdosing in the Established Status Epilepticus Treatment Trial.
Topics: Adolescent; Adult; Age Factors; Benzodiazepines; Child; Diazepam; Dose-Response Relationship, Drug; | 2021 |
Comparison of lacosamide versus sodium valproate in status epilepticus: A pilot study.
Topics: Acetamides; Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants | 2017 |
Population Pharmacokinetics and Exploratory Exposure-Response Relationships of Diazepam in Children Treated for Status Epilepticus.
Topics: Administration, Intravenous; Adolescent; Anticonvulsants; Child; Child, Preschool; Diazepam; Dose-Re | 2018 |
Comparing the efficacy of sodium valproate and levetiracetam following initial lorazepam in elderly patients with generalized convulsive status epilepticus (GCSE): A prospective randomized controlled pilot study.
Topics: Aged; Aged, 80 and over; Aging; Anticonvulsants; Dose-Response Relationship, Drug; Electroencephalog | 2019 |
Intramuscular midazolam versus intravenous lorazepam for the prehospital treatment of status epilepticus in the pediatric population.
Topics: Administration, Intravenous; Adolescent; Allied Health Personnel; Anticonvulsants; Child; Child, Pre | 2015 |
Accounting for repeat enrollments during an emergency clinical trial: the Rapid Anticonvulsant Medications Prior to Arrival Trial (RAMPART).
Topics: Adult; Aged; Allied Health Personnel; Anticonvulsants; Double-Blind Method; Female; Humans; Injectio | 2015 |
Management of generalised convulsive status epilepticus (SE): A prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam--Pilot study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Drug Therapy, Combination; Electroencephalography; Epileps | 2015 |
A comparison of four antiepileptic drugs in status epilepticus: experience from India.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Female; Humans; India; Infant; Le | 2016 |
Making Sense of a Negative Clinical Trial Result: A Bayesian Analysis of a Clinical Trial of Lorazepam and Diazepam for Pediatric Status Epilepticus.
Topics: Adolescent; Anticonvulsants; Bayes Theorem; Child; Child, Preschool; Data Interpretation, Statistica | 2017 |
Lorazepam versus diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children: a randomized controlled trial.
Topics: Algorithms; Anticonvulsants; Child; Child, Preschool; Diazepam; Drug Therapy, Combination; Electroen | 2010 |
Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Female; Humans; Infant; Levetirac | 2012 |
RAMPART (Rapid Anticonvulsant Medication Prior to Arrival Trial): a double-blind randomized clinical trial of the efficacy of intramuscular midazolam versus intravenous lorazepam in the prehospital treatment of status epilepticus by paramedics.
Topics: Allied Health Personnel; Anticonvulsants; Emergency Medical Services; Humans; Injections, Intramuscu | 2011 |
Intramuscular versus intravenous therapy for prehospital status epilepticus.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Double-Blind Method; Emergency Medical | 2012 |
Comparative trial of intravenous lorazepam and clonazepam im status epilepticus.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Benzodiazepinones; Child; Clinical Trials as Topic; Clonazep | 1981 |
Double-blind study of lorazepam and diazepam in status epilepticus.
Topics: Anti-Anxiety Agents; Clinical Trials as Topic; Diazepam; Double-Blind Method; Female; Humans; Infusi | 1983 |
Lorazepam versus diazepam in the acute treatment of epileptic seizures and status epilepticus.
Topics: Administration, Rectal; Child, Preschool; Diazepam; Epilepsy; Female; Humans; Injections, Intravenou | 1995 |
A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group.
Topics: Aged; Anticonvulsants; Diazepam; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Inj | 1998 |
A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus.
Topics: Adult; Anticonvulsants; Diazepam; Double-Blind Method; Emergency Medical Services; Emergency Medical | 2001 |
Comparative audit of intravenous lorazepam and diazepam in the emergency treatment of convulsive status epilepticus in children.
Topics: Anticonvulsants; Child; Child, Preschool; Diazepam; Emergency Medical Services; Female; Humans; Infa | 2002 |
103 other studies available for lorazepam and Status Epilepticus
| Article | Year |
|---|---|
Resolution of status epilepticus after ketamine administration.
Topics: Aftercare; Anticonvulsants; COVID-19; Female; Humans; Infant; Ketamine; Levetiracetam; Lorazepam; Pa | 2022 |
Prehospital Treatment of Status Epilepticus in the United States.
Topics: Anticonvulsants; Benzodiazepines; Diazepam; Emergency Medical Services; Guideline Adherence; Humans; | 2021 |
Pharmacist involvement with antiepileptic therapy for status epilepticus in the emergency department.
Topics: Adult; Anticonvulsants; Emergency Service, Hospital; Humans; Lorazepam; Retrospective Studies; Statu | 2022 |
A Comparative Study on Intranasal Versus Intravenous Lorazepam in the Management of Acute Seizure in Children.
Topics: Administration, Intranasal; Anticonvulsants; Child; Cross-Sectional Studies; Humans; Lorazepam; Seiz | 2021 |
The Midazolam RAMPART Study Medical Records Project: A Unique Use of Real-World Data in a Complex Collaborative Partnership to Support a New Drug Application.
Topics: Clinical Trials as Topic; Humans; Lorazepam; Medical Records; Midazolam; Retrospective Studies; Stat | 2023 |
Evaluation of intravenous lorazepam dosing strategies and the incidence of refractory status epilepticus.
Topics: Anticonvulsants; Humans; Incidence; Lorazepam; Retrospective Studies; Status Epilepticus | 2023 |
Sublingual lorazepam as rescue therapy for seizure emergencies in adults.
Topics: Adult; Anticonvulsants; Diazepam; Emergencies; Epilepsy; Humans; Lorazepam; Retrospective Studies; S | 2023 |
Antagonism of P2X7 receptors enhances lorazepam action in delaying seizure onset in an in vitro model of status epilepticus.
Topics: Animals; Lorazepam; Male; Membrane Proteins; Mice; Purinergic P2X Receptor Antagonists; Receptors, P | 2023 |
Active Seizures in Children Are Often Subtle and Unrecognized by Prehospital Providers.
Topics: Administration, Intravenous; Adolescent; Anticonvulsants; Child; Child, Preschool; Early Diagnosis; | 2019 |
Infant with status epilepticus secondary to systemic lidocaine toxicity from topical application.
Topics: Administration, Topical; Anticonvulsants; Diagnosis, Differential; Female; Humans; Infant; Lidocaine | 2020 |
Cefepime-Induced Neurotoxicity Presenting with Nonconvulsive Status Epilepticus Admitted as a Stroke Alert.
Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; Anticonvulsants; Aphasia; Brain Diseases; Cefepime | 2020 |
In-vitro and in-vivo evaluation of chitosan-based thermosensitive gel containing lorazepam NLCs for the treatment of status epilepticus.
Topics: Administration, Intranasal; Animals; Chitosan; Gels; Lipids; Lorazepam; Male; Nanostructures; Partic | 2020 |
Lorazepam timing for acute convulsive seizure control (LoTASC).
Topics: Acute Disease; Adult; Aged; Anticonvulsants; Benzodiazepines; Diazepam; Female; Humans; Lorazepam; M | 2020 |
Statewide Emergency Medical Services Protocols for Status Epilepticus Management.
Topics: Administration, Intranasal; Administration, Rectal; Adult; Anticonvulsants; Benzodiazepines; Child; | 2021 |
Recognition and treatment of status epilepticus in the prehospital setting.
Topics: Aged; Emergency Medical Services; Hospital Mortality; Humans; Lorazepam; Retrospective Studies; Stat | 2021 |
Intramuscular Lorazepam for Status Epilepticus in Children With Complex Medical and Physical Disabilities.
Topics: Administration, Rectal; Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Diazepam; Dose- | 2017 |
Randomized controlled trials in status epilepticus: Size matters.
Topics: Anticonvulsants; Humans; Lorazepam; Randomized Controlled Trials as Topic; Status Epilepticus | 2017 |
Inadequate benzodiazepine dosing may result in progression to refractory and non-convulsive status epilepticus.
Topics: Adult; Aged; Anticonvulsants; Benzodiazepines; Coma; Disease Progression; Drug Resistant Epilepsy; F | 2018 |
De novo absence status epilepticus in three paediatric patients: a new idiopathic epilepsy syndrome?
Topics: Anticonvulsants; Brain; Child; Child, Preschool; Electroencephalography; Epilepsy, Absence; Female; | 2018 |
Emergency Medical Services Protocols for Generalized Convulsive Status Epilepticus.
Topics: Administration, Intravenous; Anticonvulsants; California; Clinical Protocols; Diazepam; Emergency Me | 2019 |
[Efficacy and Safety of Lorazepam Intravenously Administered in Subjects with Status Epilepticus or Repetitive Seizures].
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Humans; Injections, Intravenous; Loraze | 2019 |
Comparison of intranasal midazolam versus intravenous lorazepam for seizure termination and prevention of seizure clusters in the adult epilepsy monitoring unit.
Topics: Administration, Intranasal; Administration, Intravenous; Adult; Anticonvulsants; Epilepsy; Female; H | 2019 |
Status epilepticus in a child secondary to ingestion of skin-lightening cream.
Topics: Anticonvulsants; Ataxia; Eating; Emergencies; Humans; Hydroquinones; Infant; Intubation, Intratrache | 2013 |
Formulation and optimization of polymeric nanoparticles for intranasal delivery of lorazepam using Box-Behnken design: in vitro and in vivo evaluation.
Topics: Administration, Intranasal; Animals; Chemistry, Pharmaceutical; Drug Delivery Systems; Humans; Loraz | 2014 |
Treatments for pediatric status epilepticus.
Topics: Anticonvulsants; Diazepam; Female; Humans; Lorazepam; Male; Status Epilepticus | 2014 |
Treatments for pediatric status epilepticus--reply.
Topics: Anticonvulsants; Diazepam; Female; Humans; Lorazepam; Male; Status Epilepticus | 2014 |
Exception from informed consent: ethics and logistics.
Topics: Allied Health Personnel; Anticonvulsants; Clinical Trials as Topic; Emergency Service, Hospital; Fem | 2015 |
Practice variability and efficacy of clonazepam, lorazepam, and midazolam in status epilepticus: A multicenter comparison.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Benzodiazepines; Clonazepam; Cohort Studies; Female | 2015 |
Lorazepam v. diazepam for pediatric status epilepticus.
Topics: Anticonvulsants; Child, Preschool; Diazepam; Female; Humans; Infant; Lorazepam; Male; Randomized Con | 2016 |
Comparison of short-term effects of midazolam and lorazepam in the intra-amygdala kainic acid model of status epilepticus in mice.
Topics: Amygdala; Animals; Anticonvulsants; Benzodiazepines; Disease Models, Animal; Hippocampus; Kainic Aci | 2015 |
Making SENSE--Sustained Effort Network for treatment of Status Epilepticus as a multicenter prospective registry.
Topics: Adult; Aged; Anticonvulsants; Diazepam; Female; Humans; Lorazepam; Male; Midazolam; Middle Aged; Phe | 2015 |
Status epilepticus in scrub typhus.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Female; Humans; Longitudinal Studies; Lorazepam; Male; Mid | 2016 |
Bursts of high-frequency repetitive transcranial magnetic stimulation (rTMS), together with lorazepam, suppress seizures in a rat kainate status epilepticus model.
Topics: Animals; Anticonvulsants; Combined Modality Therapy; Disease Models, Animal; Kainic Acid; Lorazepam; | 2016 |
Status epilepticus in central nervous system infections: an experience from a developing country.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Central Nervous System Infections; Developing Countries; D | 2008 |
Treatment of community-onset childhood convulsive status epilepticus.
Topics: Administration, Rectal; Anticonvulsants; Child; Diazepam; Humans; Injections, Intravenous; Lorazepam | 2009 |
ICTAL aphasia as manifestation of partial status epilepticus in a long-lasting misdiagnosed symptomatic epilepsy: an emblematic case.
Topics: Anticonvulsants; Aphasia; Brain; Carbamazepine; Electroencephalography; Humans; Lorazepam; Magnetic | 2009 |
25-year-old woman with new-onset seizures.
Topics: Adult; Anticonvulsants; Carcinoma, Basal Cell; Female; Humans; Lamotrigine; Leukemia, Myeloid, Acute | 2009 |
Perceived challenges to obtaining informed consent for a time-sensitive emergency department study of pediatric status epilepticus: results of two focus groups.
Topics: Anticonvulsants; Attitude of Health Personnel; Emergency Service, Hospital; Female; Focus Groups; Hu | 2009 |
An electronic regulatory document management system for a clinical trial network.
Topics: Anticonvulsants; Cerebral Infarction; Clinical Trials Data Monitoring Committees; Data Collection; D | 2010 |
[Use of injectable lorazepam in status epilepticus: a comparative study in French-speaking hospitals].
Topics: Anticonvulsants; Belgium; Canada; Diazepam; Drug Utilization; France; Guidelines as Topic; Health Ca | 2010 |
Persistent focal seizures after cat scratch encephalopathy.
Topics: Acyclovir; Anti-Bacterial Agents; Anticonvulsants; Antiviral Agents; Cat-Scratch Disease; Ceftriaxon | 2010 |
High-dose lorazepam for convulsive status epilepticus in an infant with holoprosencephaly.
Topics: Anticonvulsants; Female; Holoprosencephaly; Humans; Infant; Lorazepam; Status Epilepticus | 2010 |
Status epilepticus associated with borage oil ingestion.
Topics: Acyclovir; Adult; Anticonvulsants; Borago; Diethylcarbamazine; Drug Therapy, Combination; Female; ga | 2011 |
Subacute encephalopathy and seizures in alcoholics (SESA) presenting with non-convulsive status epilepticus.
Topics: Acetamides; Alcohol Withdrawal Seizures; Alcoholism; Anticonvulsants; Brain Diseases; Confusion; Dif | 2011 |
Confusion and SIRPIDs regress with parenteral lorazepam.
Topics: Aged; Anticoagulants; Anticonvulsants; Confusion; Consciousness Disorders; Diabetes Complications; E | 2011 |
Where has all the lorazepam gone?
Topics: Drug Industry; Humans; Lorazepam; Status Epilepticus; United Kingdom | 2011 |
Status epilepticus-induced hyperemia and brain tissue hypoxia after cardiac arrest.
Topics: Aged, 80 and over; Body Temperature; Brain; Cerebrovascular Circulation; Electroencephalography; Hum | 2011 |
Pharmacokinetics of intravenous lorazepam in pediatric patients with and without status epilepticus.
Topics: Adolescent; Child; Child, Preschool; Humans; Infant; Infusions, Intravenous; Lorazepam; Prospective | 2012 |
Seizure suppression and neuroprotection by targeting the purinergic P2X7 receptor during status epilepticus in mice.
Topics: Adenosine Triphosphate; Animals; Anticonvulsants; Cells, Cultured; Excitatory Amino Acid Agonists; G | 2012 |
Intramuscular versus intravenous benzodiazepines for prehospital treatment of status epilepticus.
Topics: Anticonvulsants; Emergency Medical Services; Female; Humans; Infusions, Intravenous; Injections, Int | 2012 |
[Delirium caused by nonconvulsive status epilepticus].
Topics: Affect; Aged; Anticonvulsants; Antipsychotic Agents; Brain Edema; Confusion; Delirium; Dibenzothiaze | 2012 |
Intramuscular versus intravenous benzodiazepines for status epilepticus.
Topics: Anticonvulsants; Emergency Medical Services; Female; Humans; Infusions, Intravenous; Injections, Int | 2012 |
Intramuscular versus intravenous benzodiazepines for status epilepticus.
Topics: Anticonvulsants; Emergency Medical Services; Female; Humans; Infusions, Intravenous; Injections, Int | 2012 |
Treatment of status epilepticus: an international survey of experts.
Topics: Administration, Intravenous; Adult; Anticonvulsants; Child; Consensus; Expert Testimony; Humans; Hyp | 2013 |
Treatment of out-of-hospital status epilepticus with diazepam rectal gel.
Topics: Administration, Rectal; Adult; Anticonvulsants; Assisted Living Facilities; Diazepam; Emergency Medi | 2003 |
Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity.
Topics: Adult; Anticonvulsants; Atrophy; Brain; Electroencephalography; Excitatory Amino Acid Antagonists; H | 2003 |
Nonconvulsive status epilepticus due to cefepime in a patient with normal renal function.
Topics: Aged; Anti-Bacterial Agents; Anticonvulsants; Cefepime; Cephalosporins; Electroencephalography; Fema | 2006 |
[Management of status epilepticus].
Topics: Adult; Age Factors; Aged; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Child; Diazepam; Dr | 2005 |
Prolonged confusional state following electroconvulsive therapy--diagnostic clues from serial electroencephalography.
Topics: Amnesia; Anticonvulsants; Cognition; Confusion; Depressive Disorder, Major; Electroconvulsive Therap | 2005 |
Treatment of status epilepticus in adults: guidelines of the Italian League against Epilepsy.
Topics: Adult; Age Factors; Anesthesia, General; Anticonvulsants; Benzodiazepines; Humans; International Age | 2006 |
Development of pharmacoresistance to benzodiazepines but not cannabinoids in the hippocampal neuronal culture model of status epilepticus.
Topics: Action Potentials; Animals; Animals, Newborn; Anticonvulsants; Benzodiazepines; Benzoxazines; Calciu | 2007 |
Simultaneous toxicities in a child on multiple anticonvulsants.
Topics: Anticonvulsants; Bone Marrow; Bone Marrow Diseases; Chemical and Drug Induced Liver Injury; Child, P | 2008 |
Should we accept the status quo? Time for new trials in status epilepticus.
Topics: Adult; Anticonvulsants; Electroencephalography; Epilepsy, Complex Partial; Humans; Infusions, Intrav | 2008 |
Re: New lessons: classic treatments in convulsive status epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Diazepam; Humans; Lorazepam; Phenytoin; Status Epilepticus; Valpro | 2008 |
Lorazepam in therapy for status epilepticus.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Apnea; Drug Therapy, Combination; Humans; Hypotension; Loraz | 1980 |
[Comparative study of the intravenous injection of lorazepam and clonazepam in status epilepticus].
Topics: Anti-Anxiety Agents; Benzodiazepinones; Clonazepam; Electrocardiography; Female; Humans; Injections, | 1980 |
Clinical studies of lorazepam in status epilepticus.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Child; Child, Preschool; Humans; Infant; Infant, Newbo | 1983 |
Treatment of status epilepticus with lorazepam.
Topics: Adult; Aged; Anticonvulsants; Female; Humans; Lorazepam; Male; Middle Aged; Respiration Disorders; S | 1984 |
Therapy of status epilepticus.
Topics: Anticonvulsants; Diazepam; Epilepsies, Partial; Epilepsy, Tonic-Clonic; Humans; Lorazepam; Paraldehy | 1982 |
Current concepts in neurology: management of status epilepticus.
Topics: Anticonvulsants; Diazepam; Drug Administration Schedule; Humans; Lorazepam; Phenobarbital; Phenytoin | 1982 |
Management of status epilepticus.
Topics: Diazepam; Humans; Lorazepam; Oxygen Inhalation Therapy; Status Epilepticus | 1982 |
Lorazepam for status epilepticus.
Topics: Humans; Lorazepam; Status Epilepticus | 1995 |
Diazepam or lorazepam for prolonged seizures?
Topics: Brain; Diazepam; Electroconvulsive Therapy; Electroencephalography; Emergencies; Humans; Infusions, | 1994 |
High-dose intravenous lorazepam for the treatment of refractory status epilepticus.
Topics: Adult; Aged; Aged, 80 and over; Electroencephalography; Humans; Infusions, Intravenous; Lorazepam; M | 1994 |
Fatality secondary to massive overdose of dimenhydrinate.
Topics: Adult; Arrhythmias, Cardiac; Cardiopulmonary Resuscitation; Charcoal; Colon; Dimenhydrinate; Diphenh | 1993 |
Development of a piglet model of status epilepticus: preliminary results.
Topics: Animals; Bicuculline; Diazepam; Hemodynamics; Lorazepam; Models, Biological; Pilot Projects; Respira | 1993 |
Nonconvulsive status epilepticus in the emergency room.
Topics: Adult; Aged; Anticonvulsants; Confusion; Diagnosis, Differential; Diazepam; Drug Therapy, Combinatio | 1996 |
High-performance liquid chromatographic determination of midazolam in rat brain.
Topics: Animals; Anti-Anxiety Agents; Brain Chemistry; Chromatography, High Pressure Liquid; Diazepam; Disea | 1996 |
Nonconvulsive status epilepticus after intravenous contrast medium administration.
Topics: Brain Neoplasms; Contrast Media; Diatrizoate Meglumine; Electroencephalography; Glioblastoma; Humans | 1996 |
Nonconvulsive status epilepticus.
Topics: Anticonvulsants; Dizziness; Electroencephalography; Emergency Service, Hospital; Epilepsy, Tonic-Clo | 1997 |
Status epilepticus.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Child; Humans; Infusions, Intravenous; Lorazepam; P | 1998 |
Initial treatment of generalized convulsive status epilepticus.
Topics: Adolescent; Adult; Anticonvulsants; Diazepam; Double-Blind Method; Electroencephalography; Emergenci | 1999 |
Convulsive status epilepticus following abrupt high-dose benzodiazepine discontinuation.
Topics: Adult; Anti-Anxiety Agents; Dose-Response Relationship, Drug; Epilepsy, Tonic-Clonic; Female; Flunit | 2000 |
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Lorazepam or diazepam for generalised convulsions in adults.
Topics: Diazepam; Emergency Medical Services; Epilepsy, Generalized; Epilepsy, Tonic-Clonic; Evidence-Based | 2001 |
Clinical research on out-of-hospital emergency care.
Topics: Anticonvulsants; Clinical Trials as Topic; Diazepam; Emergency Medical Services; Emergency Medical T | 2001 |
Seizures may be safely treated en route to hospital.
Topics: Anticonvulsants; Diazepam; Emergency Medical Services; Humans; Injections, Intravenous; Lorazepam; S | 2001 |
De novo absence status of late onset following withdrawal of lorazepam: a case report.
Topics: Age of Onset; Aged; Anti-Anxiety Agents; Anxiety Disorders; Confusion; Diagnosis, Differential; Elec | 2001 |
Treatment of out-of-hospital status epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Diazepam; Humans; Lorazepam; Research Design; Status Epilepticus; | 2001 |
The use of Lorazepam in status epilepticus.
Topics: Anticonvulsants; Central Nervous System; Humans; Lorazepam; Status Epilepticus | 2001 |
A comparison of lorazepam and diazepam as initial therapy in convulsive status epilepticus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Chi-Square Distribution; Costs and Cost | 2002 |
Recurrent complex partial status epilepticus associated with tiagabine rechallenge.
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dose-Response | 2002 |
Lorazepam in status epilepticus.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Child; Humans; Lorazepam; Middle Aged; Status Epilepti | 1979 |
[Convulsive status].
Topics: Diazepam; Humans; Lorazepam; Paraldehyde; Phenobarbital; Phenytoin; Status Epilepticus | 1990 |
Lorazepam treatment of experimental status epilepticus in the rat: relevance to clinical practice.
Topics: Animals; Brain; Disease Models, Animal; Lorazepam; Rats; Rats, Inbred Strains; Status Epilepticus | 1990 |
Emergency management of seizures: an overview.
Topics: Diazepam; Emergencies; Humans; Lidocaine; Lorazepam; Phenytoin; Prodrugs; Seizures; Status Epileptic | 1989 |
Lorazepam therapy of status epilepticus in children and adolescents.
Topics: Adolescent; Child; Child, Preschool; Drug Evaluation; Epilepsies, Partial; Epilepsy, Absence; Epilep | 1986 |
High-dose lorazepam therapy for status epilepticus in a pediatric patient.
Topics: Adolescent; Humans; Lorazepam; Male; Status Epilepticus | 1988 |
Determination of lorazepam in plasma of patients during status epilepticus by high-performance liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Humans; Injections, Intravenous; Lorazepam; Spectrophotometry, | 1988 |
Generalized status myoclonicus in acute anoxic and toxic-metabolic encephalopathies.
Topics: Adult; Aged; Anticonvulsants; Brain Diseases, Metabolic; Electroencephalography; Female; Humans; Hyp | 1988 |
[Status epilepticus caused by abstinence from lorazepam].
Topics: Adult; Female; Humans; Lorazepam; Status Epilepticus; Substance Withdrawal Syndrome | 1987 |
Lorazepam in childhood status.
Topics: Animals; Child; Drug Tolerance; Humans; Lorazepam; Mice; Status Epilepticus | 1987 |
Lorazepam in childhood status epilepticus and serial seizures: effectiveness and tachyphylaxis.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Female; Humans; Infant; Lorazepam; Male; Seizu | 1987 |
Lorazepam in myoclonic seizures after cardiac arrest.
Topics: Aged; Heart Arrest; Humans; Lorazepam; Middle Aged; Myoclonus; Status Epilepticus | 1986 |